Medivir Prioritises R&D by Divesting Mature Biophausia Portfolio
By Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 11 (Table of Contents)
Published: 18 Nov-2016
DOI: 10.3833/pdr.v2016.i11.2207 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Repositioning itself as an oncology-focused biotech company, Sweden-based Medivir has agreed to divest its wholly owned subsidiary Biophausia, which markets the company’s branded portfolio within the Nordic countries, to Karo Pharma for SEK908 M (US$101 M) in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS